New drug aims to shield patients from chemo's harsh side effects
NCT ID NCT07160283
Summary
This study is testing whether a drug called trilaciclib can protect patients' bone marrow from damage caused by chemotherapy. It focuses on people with advanced bile duct or pancreatic cancer. The main goal is to see if it reduces severe drops in white blood cells, a common and dangerous side effect of chemo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.